Neoadjuvant intra-arterial chemotherapy in inflammatory carcinoma of the breast
| Autor: | L. Muñoz-Galindo, F. Mansilla, J. M. Vieitez, José Ignacio Bilbao, Jesús M. Longo, J. Rebollo |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
medicine.medical_specialty Mitomycin medicine.medical_treatment Mammary gland Breast Neoplasms ThioTEPA Gastroenterology Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intra-Arterial Radiology Nuclear Medicine and imaging Mammary Arteries Aged Cisplatin Chemotherapy business.industry General Medicine Middle Aged medicine.disease Surgery medicine.anatomical_structure Chemotherapy Adjuvant Doxorubicin Toxicity Female Fluorouracil Breast carcinoma business Inflammatory Breast Carcinoma Thiotepa medicine.drug |
| Zdroj: | The British Journal of Radiology. 65:248-251 |
| ISSN: | 1748-880X 0007-1285 |
| Popis: | From 1982 to 1989, 18 eligible patients (median age 50.5 years, range 30–72 years) with inflammatory breast carcinoma have been treated with neoadjuvant intra-arterial (IA) chemotherapy. The treatment regimen includes IA cisplatin, adriamycin, mytomycin C and thiotepa on Day 1 and intravenous 5-fluorouracil on Days 1 and 2. An objective clinical response rate of 100% (eight complete and 10 partial) has been observed. The median disease-free and overall survivals are 27 months (range 5–85 + months) and 33 months (range 8–85 + months), respectively. With a median follow-up of 21.5 months, six (33.3%) patients remain alive and free of disease and 12 patients have died because of distant metastases. No local recurrences have been observed. Intra-arterial chemotherapy is an attractive technique for the treatment of locally advanced breast carcinoma with mild toxicity and high local control rate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|